CN1191849C - Chinese medicine for treating breast disease - Google Patents
Chinese medicine for treating breast disease Download PDFInfo
- Publication number
- CN1191849C CN1191849C CNB031196810A CN03119681A CN1191849C CN 1191849 C CN1191849 C CN 1191849C CN B031196810 A CNB031196810 A CN B031196810A CN 03119681 A CN03119681 A CN 03119681A CN 1191849 C CN1191849 C CN 1191849C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- preparation
- nodules
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 208000030270 breast disease Diseases 0.000 title description 2
- 210000000481 breast Anatomy 0.000 claims abstract description 53
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 241000218176 Corydalis Species 0.000 claims abstract description 16
- 206010054107 Nodule Diseases 0.000 claims description 49
- 239000002775 capsule Substances 0.000 claims description 46
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 25
- 241000255791 Bombyx Species 0.000 claims description 20
- 241000628997 Flos Species 0.000 claims description 15
- 239000000341 volatile oil Substances 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 238000001256 steam distillation Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 230000002879 macerating effect Effects 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 6
- 230000006837 decompression Effects 0.000 claims description 5
- -1 electuary Substances 0.000 claims description 5
- 238000007654 immersion Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 241001523579 Ostrea Species 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 2
- 229940023488 pill Drugs 0.000 claims 2
- 239000002994 raw material Substances 0.000 claims 2
- 229940046011 buccal tablet Drugs 0.000 claims 1
- 239000006189 buccal tablet Substances 0.000 claims 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 241000510667 Conioselinum Species 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000220317 Rosa Species 0.000 abstract 1
- 241000270666 Testudines Species 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 239000000052 vinegar Substances 0.000 description 12
- 235000021419 vinegar Nutrition 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 229940079593 drug Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000008971 rukuaixiao Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 210000005075 mammary gland Anatomy 0.000 description 6
- 230000037040 pain threshold Effects 0.000 description 6
- 235000009161 Espostoa lanata Nutrition 0.000 description 5
- 240000001624 Espostoa lanata Species 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 206010006298 Breast pain Diseases 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 4
- 208000006662 Mastodynia Diseases 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012567 medical material Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000003163 gonadal steroid hormone Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006223 Breast discharge Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000000114 Pain Threshold Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a traditional Chinese medicine for treating nodules of breasts, particularly to a compound traditional Chinese medicine preparation which is prepared from spica prunellae, hemlock parsley, stiff silkworm, turtle shell, bupleurum root, red peony root, rose, zedoary, angelica, corydalis tuber, oyster shell, etc.
Description
Technical field:
The present invention relates to a kind of Chinese medicine for the treatment of nodules of the breast, particularly a kind of compound Chinese medicinal preparation of making by Chinese crude drugs such as Spica Prunellae, Rhizoma Chuanxiong, Bombyx Batryticatus, Carapax Trionycis, Radix Bupleuri, Radix Paeoniae Rubra, Flos Rosae Rugosae, Rhizoma Curcumae, Radix Angelicae Sinensis, Rhizoma Corydalis, Concha Ostreaes.
Background technology:
Development along with society, the change of people's dietary structure, cyclomastopathy is progressively ascendant trend, women's physical and mental health and safety in serious threat, accounted for first of women's malignant tumor in China's breast carcinoma, so excavate and study the new drug of treatment mastopathy, the mammary gland precancerosis is treated, be imperative work.The traditional Chinese medical science thinks that the main diseases that nodules of the breast takes place is because of being depressed emotion, and depression of liver-QI and then stagnation of QI expectorant coagulate, phlegm and blood stasis, and clinical symptoms is the Ruzhong caking, mastalgia from dialectical, is controlled suitable promoting flow of QI and blood, softening the hard mass, eliminating stagnation.At present, though the Chinese medicine of the treatment nodules of the breast of some listings is arranged, some belongs to cures the symptoms, not the disease, and some uses expensive composition, and some is cut and interrupt using owing to uncertain therapeutic efficacy in application process.
The invention provides a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect.
Summary of the invention:
The invention provides a kind of Chinese medicine preparation of new treatment nodules of the breast, Chinese medicine of the present invention has the effect of promoting flow of QI and blood, hard masses softening and resolving, is used for mastalgia that syndrome of qi stagnation and blood stasis causes, lump in breast, dark etc. with nipple discharge, irritated irritability, fullness and distention in the chest and hypochondrium, the few color of menstrual blood volume.
Chinese medicine preparation of the present invention by Chinese crude drugs such as Spica Prunellae, Rhizoma Chuanxiong, Bombyx Batryticatus, Carapax Trionycis, Radix Bupleuri, Radix Paeoniae Rubra, Flos Rosae Rugosae, Rhizoma Curcumae, Radix Angelicae Sinensis, Rhizoma Corydalis, Concha Ostreaes through being processed into.
Chinese medicine preparation of the present invention, its prescription consists of:
Spica Prunellae 148-594 part Rhizoma Chuanxiong 99-396 part Bombyx Batryticatus 59-238 part
Carapax Trionycis 148-594 part Radix Bupleuri 99-396 part Radix Paeoniae Rubra 89-356 part
Flos Rosae Rugosae 119-476 part Rhizoma Curcumae 89-356 part Radix Angelicae Sinensis 99-396 part
Rhizoma Corydalis 89-356 part Concha Ostreae 148-594 part.
Preferably
Spica Prunellae 222-396 part Rhizoma Chuanxiong 148-264 part Bombyx Batryticatus 89-158 part
Carapax Trionycis 222-396 part Radix Bupleuri 148-264 part Radix Paeoniae Rubra 133-237 part
Flos Rosae Rugosae 178-317 part Rhizoma Curcumae 133-237 part Radix Angelicae Sinensis 148-264 part
Rhizoma Corydalis 133-237 part Concha Ostreae 222-396 part.
More preferably
119 parts of 198 parts of Bombyx Batryticatus of 297 parts of Rhizoma Chuanxiongs of Spica Prunellae
178 parts of 198 parts of Radix Paeoniae Rubra of 297 parts of Radix Bupleuri of Carapax Trionycis
198 parts of 178 parts of Radix Angelicae Sinensis of 238 parts of Rhizoma Curcumae of Flos Rosae Rugosae
297 parts of 178 portions of Concha Ostreaes of Rhizoma Corydalis.
Chinese medicine preparation of the present invention can be prepared by following method:
More than ten simply, Bombyx Batryticatus is ground into fine powder, surplus medicated powder is broken into coarse powder.Get Carapax Trionycis, Concha Ostreae adds 4 times of water gagings, decocts 1 hour, and is standby; Spica Prunellae, Radix Bupleuri, Radix Paeoniae Rubra, Rhizoma Curcumae steam distillation extract volatile oil, medicinal residues and decocting liquid and Carapax Trionycis, the Concha Ostreae thing mixing and water adding that is decocted first decocts three times, is respectively collecting decoction 1.5 hours, 2.5 hours, 1.5 hours, centrifugal, the supernatant concentrating under reduced pressure becomes extractum; Rhizoma Chuanxiong, Flos Rosae Rugosae, Radix Angelicae Sinensis steam distillation extract volatile oil, and medicinal residues and decocting liquid and Rhizoma Corydalis merge, and adding ethanol adjustment concentration of alcohol is 70%, and the solvent total amount is 8 times of amounts of medical material.65 ℃ of warm macerating three times were respectively 1 hour, 2 hours, 0.5 hour, and immersion merges, and centrifugal, the supernatant decompression recycling ethanol also is condensed into extractum; Merge above-mentioned two kinds of extractum drying under reduced pressure, pulverize, add the Bombyx Batryticatus fine powder, mixing, spray adds volatile oil, and airtight placement obtains active constituents of medicine, and this active component is made Chinese medicine preparation of the present invention by the preparation technique of routine.
During more than prescription was formed, weight was calculated with crude drug, and as if being unit with the gram, this composition can be made into 1000 doses of pharmaceutical preparatioies, described 1000 doses of fingers, and the final drug preparation of making, as make 1000 of capsule preparations, 1000 in tablet, granule 1000g.
More than form, as if being unit with the gram, can be made into the preparation of 250 taking doses, as capsule, make 1000, each taking dose is 4, can take altogether 250 times.As granule, make 250 bags, take 1 bag at every turn, can take altogether 250 times.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each is formed should be in above-mentioned scope.Screening obtains the ratio of above weight proportion through science.
Chinese medicine preparation of the present invention, can add the medicine acceptable carrier when being prepared into medicament, described medicine acceptable carrier can be: starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Chinese medicine preparation of the present invention can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch.Preparation of the present invention, peroral dosage form preferably, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc., more preferably capsule.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but obeys every day three times, each 1-4 agent, as: 1 bag or 4 or sheet.
Chinese medicine preparation of the present invention, be called " nodules of the breast eliminating stagnation capsule " at this, clinical trial through Dongzhimen Hospital, Beijing Univ of Traditional Chinese Medicine, The People's Hospital, the hospital of traditional Chinese hospital, Xi'an, Traditional Chinese Medicine Research Institute, Shanxi Province Affiliated Hospital to nodules of the breast eliminating stagnation capsule for treating cyclomastopathy (qi stagnation blood stasis type) 320 examples, 30 examples of fully recovering, produce effects 129 examples, total obvious effective rate 49.69%, total effective rate 91.88%, compare with matched group, curative effect between the two has the significance meaning, points out this medicine that curative effect is preferably arranged.
Nodules of the breast eliminating stagnation capsule is having significant difference with matched group aspect alleviation mastalgia and the lump in breast; Simultaneous phenomenon is improved the aspect therapeutical effect is preferably also arranged.To the mastalgia degree light, in, alleviate the situation there was no significant difference between heavy; Light to the state of an illness, in, heavy in various degree between the curative effect there was no significant difference, course of disease length removes＜half a year/1 year-, difference that each organizes that there are no significant, the cyclomastopathy of this medicine to the qi stagnation blood stasis type is described, state of an illness weight no matter, course of disease length, the pain degree weight all has certain curative effect.In treatment group and the matched group blood situation of change of estradiol and progestogen before treatment, treat back self relatively and relatively there are no significant between group difference, illustrate that this medicine and contrast medication all do not have obvious influence to the estrogen and progestogen level.Recovery from illness and produce effects case with in anti-, conservation rate is that 98.11% this medicine of explanation has late result preferably.In clinical observation, this medicine does not have serious adverse effects, and the slight malaise symptoms of 5 examples is arranged in 320 examples, all can alleviate after anti symptom treatment or drug withdrawal, illustrates that this medicine has applicability preferably.To the nearly half patient treat preceding, carried out blood, urine after treating, just routine, liver, renal function and Electrocardioscopy are all no abnormal, point out this medicine not have obvious toxic and side effects, clinical practice is safer.In a word, nodules of the breast eliminating stagnation capsule for treating cyclomastopathy (qi stagnation blood stasis type) through II clinical trial phase explanation effectively, safety, easily accepted by the patient, applicability is arranged.
Below experiment further specifies the beneficial effect of Chinese medicine preparation of the present invention, experiment drug use nodules of the breast eliminating stagnation capsule, and RUKUAIXIAO is used in contrast.
One, nodules of the breast eliminating stagnation capsule is to the therapeutic effect of cyclomastopathy
1, general form is learned the influence that changes:
Result's (table 1) is through ferrum and inspection statistics, and heavy dose of group of nodules of the breast eliminating stagnation capsule and RUKUAIXIAO group and saline control group compare, and the visible nodules of the breast eliminating stagnation capsule of significant difference (P＜0.01) can suppress the rabbit mammary gland enlargement that estrogen causes.
Table 1 nodules of the breast eliminating stagnation capsule increases the influence of degree to mammary gland
Mammary gland increases degree
Group n mammary gland sum
+++ ++ + -
Normal group 6001 23 24
Matched group 6 12 741 24
Nodules of the breast eliminating stagnation capsule 0.5g/kg 68673 24
Nodules of the breast eliminating stagnation capsule 1.5g/kg 63597 24
Contrast medicine 1.5g/kg 64686 24
2. to the influence of sex hormone level:
Result's (table 2) as seen, E in the blood
2With the P level, be starkly lower than saline control group (P＜0.05 and P＜0.01) in the heavy dose of treatment group of nodules of the breast eliminating stagnation capsule, RUKUAIXIAO does not then have this effect, and nodules of the breast eliminating stagnation capsule can reduce E
2With the level of P, thereby to resisting hyperplasia of mammary glands.
Table 4 nodules of the breast eliminating stagnation capsule to the influence of sex hormone level in the cyclomastopathy rabbit body (X ± S, n=6)
Group E2 P PSH LH PRL
(pg/ml) (ng/ml) (Miu/ml) (Miu/ml) (ng/ml)
Normal group 54 ± 11 0.65 ± 0.16 1.49 ± 0.50 4.7 ± 2.0 2.69 ± 0.39
Matched group 71 ± 18 1.09 ± 0.12 2.40 ± 0.73 7.1 ± 2.2 3.76 ± 0.32
Nodules of the breast eliminating stagnation capsule (0.5g/kg) 70 ± 10 0.70 ± 0.2 1.97 ± 0.89 5.1 ± 3.1 2.44 ± 0.48
Nodules of the breast eliminating stagnation capsule (1.5g/kg) 53 ± 8* 0.50 ± 0.06** 1.57 ± 0.24 5.1 ± 0.4 2.09 ± 0.18
Contrast medicine (1.5g/kg) 86 ± 20 1.20 ± 0.38 2.51 ± 0.42 7.6 ± 1.4 2.66 ± 0.19
Compare with matched group: * P＜0.05**P＜0.01
Two, the capsular analgesic activity of nodules of the breast eliminating stagnation
1, mice hot plate method analgesic experiment
Select for use the burning pain threshold at 30s with 60 of interior female mices, be divided into 4 groups at random, 15 every group, give saline (negative control) respectively, RUKUAIXIAO (positive control), nodules of the breast eliminating stagnation capsule 1.5 and 4.5g/kg, more than respectively organize equal gastric infusion, the administration volume is 20ml/kg.With the burning pain threshold value that hot plate method (55 ± 0.5 ℃ of temperature) measures after the administration 0.5,1,2,4 respectively, 6h respectively organizes mice, allly surpass 60s person, all by 60s.Result's (table 3) shows, saline control group mice burning pain threshold value, and slightly fluctuation of test does not repeatedly have obvious statistics difference within 6h.Mice is once irritated stomach and gives nodules of the breast eliminating stagnation capsule, and its pain threshold increases.Show that nodules of the breast eliminating stagnation capsule has certain analgesia and has certain analgesic effect, and the persistent period is more of a specified duration, but onset is slower.
Table 3 nodules of the breast health is to the influence of mice burning pain threshold value
The burning pain threshold value (s, x ± s, n=15)
Group dosage
(g/kg) 0.5h 1h 2h 4h 6h
Saline group 24 ± 49 29 ± 10 26 ± 8 21 ± 9 31 ± 15
Nodules of the breast eliminating stagnation capsule 1.5 23 ± 9 27 ± 12 32 ± 14 21 ± 11 34 ± 17
Nodules of the breast eliminating stagnation capsule 4.5 19 ± 6* 35 ± 8* 39 ± 11*** 31 ± 12** 43 ± 14**
Contrast medicine 4.5 33 ± 11** 30 ± 14* 37 ± 15** 32 ± 17** 41 ± 15*
Compare with the saline group in the same time: P＞0.05, * P＜0.05, * * * P＜0.01
2, Mus is turned round the body experiment
79 of Kunming mouses, female, body weight 21.3 ± 1.3g.Be divided into saline, pethidine 50mg/kg, RUKUAIXIAO 1.5g/kg, nodules of the breast eliminating stagnation capsule 0.51.5 and 4.5g/kg group at random.Test the previous day at the upper and lower noon and test and respectively be administered once in preceding 1 hour.Ip1% acetic acid 0.1ml/10g, mouse writhing number of times in 5-10 minute after the observation injection.Result's (table 4) as seen, saline control group mice writhing response occurs behind ip 1% acetic acid, the writhing response of pethidine group mice obviously reduces.Nodules of the breast eliminating stagnation capsule and lump in breast energy dissipating reduce the writhing response of mice, and prompting nodules of the breast eliminating stagnation capsule has certain analgesic activity.
Table 4 nodules of the breast eliminating stagnation capsule is to the influence of mouse writhing reaction
Group dosage (g/kg) n always turned round body number of times (X ± S) in 5 minutes
Saline group 13 22.5 ± 4.3
Pethidine 0.05 10 0.7 ± 0.8***
Nodules of the breast eliminating stagnation capsule 0.5 14 17.5 ± 7.0*
Nodules of the breast eliminating stagnation capsule 1.5 14 16.8 ± 8.7**
Nodules of the breast eliminating stagnation capsule 4.5 14 15.0 ± 7.2**
Contrast medicine 4.5 14 15.4 ± 5.6**
Compare with the saline group: * P＞0.05, * P＜0.05, * * * P＜0.01
Three, the capsular antiinflammatory action of nodules of the breast eliminating stagnation
1, the scorching method of caused by dimethylbenzene xylene
50 of mices, female, body weight 21.2 ± 1.5g is divided into 5 groups of saline, nodules of the breast eliminating stagnation capsule (0.5,1.5,4.5g/kg) and RUKUAIXIAO 4.5g/kg etc. at random.Test proxima luce (prox. luc) and cause scorching preceding 1h ig said medicine respectively, only be applied to left ear with dimethylbenzene 0.03ml/ and cause inflammation, auris dextra in contrast.Behind the 4h, take off neck and put to death animal, cut two ears, with 8mm punch out, inflammatory reaction such as edema.Nodules of the breast eliminating stagnation capsule 1.5～4.5g/kg irritates stomach, and significantly antiinflammatory action is arranged.
Table 5 nodules of the breast eliminating stagnation capsule to the influence of Mice Auricle inflammation (X ± S, n=10)
The heavy auris dextra method of double differences of group dosage left side ear value
(g/kg) (mg) (mg)
Saline group 24.5 ± 5.4 14.9 ± 3.3 9.6 ± 3.7
Nodules of the breast eliminating stagnation capsule 0.5 23.9 ± 4.1 15.1 ± 2.4 8.8 ± 3.4*
Nodules of the breast eliminating stagnation capsule 1.5 21.8 ± 4.3 15.0 ± 2.8 6.8 ± 1.9**
Nodules of the breast eliminating stagnation capsule 4.5 20.8 ± 2.3 14.5 ± 1.2 6.3 ± 1.8**
Contrast medicine 4.5 18.2 ± 3.0 13.1 ± 1.5 5.1 ± 2.2***
Compare with the saline group: * P＞0.05, * P＜0.05, * * * P＜0.01
2, subcutaneous cotton balls implantation
32 of SD rats, female, body weight 200.6 ± 32.5g is divided into saline, nodules of the breast eliminating stagnation capsule 1.5,4.5g/kg and RUKUAIXIAO 4.5g/kg group, 8 every group at random.Under the shallow fiber crops of urethane, it is subcutaneous that two sterilization cotton balls (each adds ampicillin 1mg for the about 30 ± 1mg/ of weight, autoclaving) are implanted rat both sides groin respectively, skin suture.The art proxima luce (prox. luc) begins the ig administration, and 1 time/day, continuous 10d.24h puts to death rat after the last administration, takes out granuloma induced by implantation of cotton pellets, and 60 ℃ of baking box oven dry are weighed, and deduct the raw cotton ball weight and form index as granuloma.
Result's (table 6) shows that this experimental model is made successfully, and implanting cotton balls weight obviously increases.Nodules of the breast health 1.5g/kg, 4.5g/kg do not have obvious influence (P＞0.05) to subcutaneous rat cotton balls implantation granuloma, but the granulomatous trend of inhibition is arranged.
Table 6 nodules of the breast eliminating stagnation capsule is to the granulomatous influence of subcutaneous rat (X ± S)
Group dosage (g/kg) granuloma net weight (mg/100g body weight)
Saline group 43.7 ± 6.4
Nodules of the breast eliminating stagnation capsule 1.5 43.3 ± 8.1*
Nodules of the breast eliminating stagnation capsule 4.5 41.0 ± 6.8*
Contrast medicine 4.5 38.3 ± 9.4*
* P＞0.05 of comparing with the saline group
The specific embodiment: further specify the present invention by the following examples
Embodiment 1
The preparation of capsule
Spica Prunellae 297g Rhizoma Chuanxiong (wine is processed) 198g Bombyx Batryticatus (parched with bran) 119g
Carapax Trionycis (vinegar system) 297g Radix Bupleuri (vinegar system) 198g Radix Paeoniae Rubra (wine stir-fry) 178g
Flos Rosae Rugosae 238g Rhizoma Curcumae (vinegar system) 178g Radix Angelicae Sinensis (wine is processed) 198g
Rhizoma Corydalis (vinegar system) 178g Concha Ostreae 297g
More than ten simply, Bombyx Batryticatus is ground into fine powder, surplus medicated powder is broken into coarse powder.Get Carapax Trionycis, Concha Ostreae adds 4 times of water gagings, decocts 1 hour, and is standby; Spica Prunellae, Radix Bupleuri, Radix Paeoniae Rubra, Rhizoma Curcumae steam distillation extract volatile oil, medicinal residues and decocting liquid and Carapax Trionycis, the Concha Ostreae thing mixing and water adding that is decocted first decocts three times, is respectively collecting decoction 1.5 hours, 2.5 hours, 1.5 hours, centrifugal, the supernatant concentrating under reduced pressure becomes extractum; Rhizoma Chuanxiong, Flos Rosae Rugosae, Radix Angelicae Sinensis steam distillation extract volatile oil, and medicinal residues and decocting liquid and Rhizoma Corydalis merge, and adding ethanol adjustment concentration of alcohol is 70%, and the solvent total amount is 8 times of amounts of medical material.65 ℃ of warm macerating three times were respectively 1 hour, 2 hours, 0.5 hour, and immersion merges, and centrifugal, the supernatant decompression recycling ethanol also is condensed into extractum; Merge above-mentioned two kinds of extractum drying under reduced pressure, pulverize, add the Bombyx Batryticatus fine powder, mixing adds an amount of 75% alcohol granulation, and drying is put coldly, and spray adds volatile oil, and airtight placement adds an amount of magnesium stearate, and is encapsulated, makes 1000, promptly.
Embodiment 2
The preparation of tablet
Spica Prunellae 297g Rhizoma Chuanxiong (wine is processed) 198g Bombyx Batryticatus (parched with bran) 119g
Carapax Trionycis (vinegar system) 297g Radix Bupleuri (vinegar system) 198g Radix Paeoniae Rubra (wine stir-fry) 178g
Flos Rosae Rugosae 238g Rhizoma Curcumae (vinegar system) 178g Radix Angelicae Sinensis (wine is processed) 198g
Rhizoma Corydalis (vinegar system) 178g Concha Ostreae 297g
More than ten simply, Bombyx Batryticatus is ground into fine powder, surplus medicated powder is broken into coarse powder.Get Carapax Trionycis, Concha Ostreae adds 4 times of water gagings, decocts 1 hour, and is standby; Spica Prunellae, Radix Bupleuri, Radix Paeoniae Rubra, Rhizoma Curcumae steam distillation extract volatile oil, medicinal residues and decocting liquid and Carapax Trionycis, the Concha Ostreae thing mixing and water adding that is decocted first decocts three times, is respectively collecting decoction 1.5 hours, 2.5 hours, 1.5 hours, centrifugal, the supernatant concentrating under reduced pressure becomes extractum; Rhizoma Chuanxiong, Flos Rosae Rugosae, Radix Angelicae Sinensis steam distillation extract volatile oil, and medicinal residues and decocting liquid and Rhizoma Corydalis merge, and adding ethanol adjustment concentration of alcohol is 70%, and the solvent total amount is 8 times of amounts of medical material.65 ℃ of warm macerating three times were respectively 1 hour, 2 hours, 0.5 hour, and immersion merges, and centrifugal, the supernatant decompression recycling ethanol also is condensed into extractum; Merge above-mentioned two kinds of extractum drying under reduced pressure, pulverize, add the Bombyx Batryticatus fine powder, mixing adds an amount of 75% alcohol granulation, and drying is put coldly, and spray adds volatile oil, and airtight placement adds an amount of magnesium stearate, and tabletting is made 1000, promptly.
Embodiment 3
The preparation of granule
Spica Prunellae 297g Rhizoma Chuanxiong (wine is processed) 198g Bombyx Batryticatus (parched with bran) 119g
Carapax Trionycis (vinegar system) 297g Radix Bupleuri (vinegar system) 198g Radix Paeoniae Rubra (wine stir-fry) 178g
Flos Rosae Rugosae 238g Rhizoma Curcumae (vinegar system) 178g Radix Angelicae Sinensis (wine is processed) 198g
Rhizoma Corydalis (vinegar system) 178g Concha Ostreae 297g
More than ten simply, Bombyx Batryticatus is ground into fine powder, surplus medicated powder is broken into coarse powder.Get Carapax Trionycis, Concha Ostreae adds 4 times of water gagings, decocts 1 hour, and is standby; Spica Prunellae, Radix Bupleuri, Radix Paeoniae Rubra, Rhizoma Curcumae steam distillation extract volatile oil, medicinal residues and decocting liquid and Carapax Trionycis, the Concha Ostreae thing mixing and water adding that is decocted first decocts three times, is respectively collecting decoction 1.5 hours, 2.5 hours, 1.5 hours, centrifugal, the supernatant concentrating under reduced pressure becomes extractum; Rhizoma Chuanxiong, Flos Rosae Rugosae, Radix Angelicae Sinensis steam distillation extract volatile oil, and medicinal residues and decocting liquid and Rhizoma Corydalis merge, and adding ethanol adjustment concentration of alcohol is 70%, and the solvent total amount is 8 times of amounts of medical material.65 ℃ of warm macerating three times were respectively 1 hour, 2 hours, 0.5 hour, and immersion merges, and centrifugal, the supernatant decompression recycling ethanol also is condensed into extractum; Merge above-mentioned two kinds of extractum drying under reduced pressure, pulverize, add the Bombyx Batryticatus fine powder, mixing adds an amount of 75% alcohol granulation, and drying is put coldly, and spray adds volatile oil, and airtight placement adds an amount of sucrose 80g, and ethanol 20ml granulates, and makes the 1000g granule, adorns 250 bags, promptly.
Claims (8)
1. a Chinese medicine preparation for the treatment of nodules of the breast is characterized in that, is made by following Chinese medicine raw materials by weight proportion
Spica Prunellae 222-396 part Rhizoma Chuanxiong 148-264 part Bombyx Batryticatus 89-158 part
Carapax Trionycis 222-396 part Radix Bupleuri 148-264 part Radix Paeoniae Rubra 133-237 part
Flos Rosae Rugosae 178-317 part Rhizoma Curcumae 133-237 part Radix Angelicae Sinensis 148-264 part
Rhizoma Corydalis 133-237 part Concha Ostreae 222-396 part.
2. the Chinese medicine preparation of claim 1 is characterized in that, is made by following Chinese medicine raw materials by weight proportion
119 parts of 198 parts of Bombyx Batryticatus of 297 parts of Rhizoma Chuanxiongs of Spica Prunellae
178 parts of 198 parts of Radix Paeoniae Rubra of 297 parts of Radix Bupleuri of Carapax Trionycis
198 parts of 178 parts of Radix Angelicae Sinensis of 238 parts of Rhizoma Curcumae of Flos Rosae Rugosae
297 parts of 178 portions of Concha Ostreaes of Rhizoma Corydalis.
3. any one Chinese medicine preparation of claim 1-2 is tablet, capsule, oral liquid, buccal tablet, granule, electuary, pill, powder, suspensoid, powder, solution, drop or drop pill.
4. the Chinese medicine preparation of claim 3 is capsules.
5. the Chinese medicine preparation of claim 1 prevents and/or treats application in the medicine of nodules of the breast in preparation.
6. the preparation method of the Chinese medicine preparation of claim 1 is characterized in that, may further comprise the steps:
A. Bombyx Batryticatus is ground into fine powder, and surplus medicated powder is broken into coarse powder;
B. get Carapax Trionycis, Concha Ostreae decocts with water standby;
C. Spica Prunellae, Radix Bupleuri, Radix Paeoniae Rubra, Rhizoma Curcumae steam distillation extract volatile oil, the thing mixing and water adding decoction of being decocted first of medicinal residues and decocting liquid and Carapax Trionycis, Concha Ostreae, and collecting decoction, centrifugal, the supernatant concentrating under reduced pressure becomes extractum;
D. Rhizoma Chuanxiong, Flos Rosae Rugosae, Radix Angelicae Sinensis steam distillation extract volatile oil, and medicinal residues and decocting liquid and Rhizoma Corydalis merge, and add ethanol, warm macerating, and immersion merges, and centrifugal, the supernatant decompression recycling ethanol also is condensed into extractum;
E. merge above-mentioned two kinds of extractum drying under reduced pressure, pulverize, add the Bombyx Batryticatus fine powder, mixing, drying, spray adds volatile oil, obtains active constituents of medicine;
F. this active component mixes with the medicine acceptable carrier.
7. the preparation method of claim 6 is characterized in that, decocting with water among the step c decocts three times altogether, each decocting time 1.5～2.5 hours.
8. the preparation method of claim 6 is characterized in that, adds the ethanol warm macerating in the steps d, and warm macerating is three times altogether, and each soak time is 0.5～2 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031196810A CN1191849C (en) | 2003-03-20 | 2003-03-20 | Chinese medicine for treating breast disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031196810A CN1191849C (en) | 2003-03-20 | 2003-03-20 | Chinese medicine for treating breast disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1438027A CN1438027A (en) | 2003-08-27 |
| CN1191849C true CN1191849C (en) | 2005-03-09 |
Family
ID=27674234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031196810A Expired - Lifetime CN1191849C (en) | 2003-03-20 | 2003-03-20 | Chinese medicine for treating breast disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1191849C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101224290B (en) * | 2007-12-28 | 2010-07-14 | 李显成 | Chinese traditional medicine for treating breast nodules and preparing method thereof |
| CN102755515B (en) * | 2012-06-27 | 2013-12-18 | 蔡爱宁 | Traditional Chinese medicine decoction for treating hyperplasia of mammary glands |
| CN104524201A (en) * | 2014-12-05 | 2015-04-22 | 青岛祥翔生物医药科技有限公司 | Traditional Chinese medicine for treating mammary nodule disease of liver-qi stagnation syndrome type |
| CN107440976B (en) * | 2017-09-23 | 2021-03-30 | 东莞市白天鹅纸业有限公司 | Composition with whitening function and wet tissue containing composition |
| CN113995782B (en) * | 2021-12-07 | 2022-11-22 | 陕西白鹿制药股份有限公司 | Application of composition containing selfheal to preparation of medicine for treating thyroid nodules |
-
2003
- 2003-03-20 CN CNB031196810A patent/CN1191849C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CN1438027A (en) | 2003-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1215869C (en) | Black-bone chicken white phoenix preparation medicine and its preparing method | |
| CN1907462A (en) | Traditional Chinese medicine composition for treating hepatitis and fatty liver | |
| CN1561994A (en) | Medicinal compositon containing artemisine extract for treating rheumatoid arthritis and immunologic disease | |
| CN1150041A (en) | Chinese patent medicine for curing gallstones and kidney stones | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1191849C (en) | Chinese medicine for treating breast disease | |
| CN1283309C (en) | Pure medicinal liquor | |
| CN1248726C (en) | Medical combination possessing effect for turning cancer off and rejuvenation | |
| CN1528386A (en) | Chinese medicine composition for treating rheumatism, rheumatoid, hyperosteogeny and fracture and preparing method thereof | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1726991A (en) | Medication of treating by dysenorrhea, irregular menses, weakness after childbirth for women, and preparation method | |
| CN1907316A (en) | Orthopaedics disease treating and preventing medicinal composition | |
| CN1569095A (en) | Medicine for treating cerebral infarction | |
| CN1541691A (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN1742775A (en) | Medicine composition for preventing and treating orthopedic diseases | |
| CN1265810C (en) | A pharmaceutical composition for treating cyclomastopathy, and its preparation method | |
| CN1074679C (en) | Chinese medicine for treating bone fracture | |
| CN1205975C (en) | Chinese medicine for treating prostatitis | |
| CN1304027C (en) | Bone nourishing and rheumatic treating pills and their preparation | |
| CN1634407A (en) | Chinese traditional medicine preparation for treating cholecystitis | |
| CN1304043C (en) | Longhedan pills and their preparation | |
| CN1296091C (en) | Chinese traditional medicine composition for treating psoriasis | |
| CN1739678A (en) | Medicine for treating pain caused by wind, cold and wetness evils and its prepn | |
| CN1626210A (en) | Preparation of 'Sanjin' medication for treating diseases of urinary system and preparation method | |
| CN1446554A (en) | Medicine for treating acute cholecystitis and chronic cholecystitis and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050309 |